AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 131 min read$BBIO

Cook Jennifer E. sold $13.2M of BBIO

Cook Jennifer E. sold 148,589 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $88.54 ($84.00–$90.00, $13.16M total) across 2 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Jennifer E.
Published Jul 13, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed $13.16M open-market sale by a director can modestly influence sentiment, but it does not introduce new company fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without accompanying business or clinical news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total insider holdings beyond the post-transaction share count.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-13 for trades dated 2026-07-09

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc.

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Pharma director Jennifer E. Cook sold 148,589 shares in open-market trades under a 10b5-1 plan, totaling about $13.16M.

Expected impact

Likely limited, short-lived impact unless paired with other negative catalysts.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by a director; the article provides no new operational, clinical, or guidance information.

Market effects

Sector

Minimal, as this is company-specific insider transaction with no sector-wide regulatory or clinical signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    BridgeBio Pharma, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Jennifer E. Cook

    Director who sold 148,589 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 19
$BBIOMed

BBIO Maintained by Piper Sandler -- Price Target Raised to $120

Piper Sandler maintained an Overweight rating on BridgeBio Pharma (BBIO) and raised its price target to $120 from $115, citing growth potential in the biotech sector. The company's GF Value™ suggests it is 59.4% undervalued, but its GF Score™ indicates moderate performance with strong growth but weak financial strength. Insider selling activity totaled $4.58M over the last three months.

gurufocus.com2 min
OCT 15
$BBIOMed

H.C. Wainwright reiterates Buy on BridgeBio stock, cites trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for BridgeBio Pharma (BBIO) after positive Phase 3 trial data for encaleret. The stock trades near its fair value estimate, with a Strong Buy consensus and targets ranging from $80 to $156. BridgeBio also announced FDA acceptance of a New Drug Application for infigratinib, with a target action date in February 2027.

investing.com2 min
OCT 15
$BBIOMed

BridgeBio Pharma assumed with a Buy at UBS

UBS initiated coverage of BridgeBio Pharma (BBIO) with a Buy rating and a $92 price target, citing underestimation of its lead drug's potential. UBS projects 2035 sales of $4.1B, higher than the $3.7B consensus. The firm's optimism is based on a 50-doctor survey, comparative data, and recent real-world evidence.

tipranks.com2 min
OCT 13
$BBIOMedAI 8/10

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significa

SEC EDGAR 8-K2 min
OCT 12
$BBIOMedAI 8/10

BridgeBio Reports Encaleret Gains In ADH1; Starts RECLAIM-HP Phase 3 In Chronic Hypoparathyroidism

BridgeBio Pharma (BBIO) presented Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1, showing improved PTH levels and symptoms. The company also began a Phase 3 trial for chronic hypoparathyroidism. The FDA accepted its New Drug Application under Priority Review, with a target action date of May 8, 2027. BBIO shares closed at $65.35, up 0.48%.

rttnews.com2 min